Trial reportJournal of hematology & oncology2013
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
Trial report in Journal of hematology & oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02824471 (Sickle Cell Disease), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.BMJ open · 2020Pooled it
- Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study.British journal of haematology · 2019Trial
- Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.Clinical pharmacokinetics · 2018Trial
- A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.Thrombosis research · 2013Trial
- Platelet Aggregation Studies and Coagulation Profile in Sickle Cell Disease in Symptomatic and Steady State Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease.JCI insight · 2024Article
- Effects of antiplatelet therapy on menstrual blood loss in reproductive-aged women: a systematic review.Research and practice in thrombosis and haemostasis · 2024Article
- From Stress to Sick(le) and Back Again-Oxidative/Antioxidant Mechanisms, Genetic Modulation, and Cerebrovascular Disease in Children with Sickle Cell Anemia.Antioxidants (Basel, Switzerland) · 2023Review
- Hope on the Horizon: New and Future Therapies for Sickle Cell Disease.Journal of clinical medicine · 2023Review
- Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events.Journal of translational medicine · 2021Review
- Sickle cell vaso-occlusion: The dialectic between red cells and white cells.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Role of the coagulation system in the pathogenesis of sickle cell disease.Blood advances · 2019Article
- Emerging disease-modifying therapies for sickle cell disease.Haematologica · 2019Review
- Therapeutic strategies for sickle cell disease: towards a multi-agent approach.Nature reviews. Drug discovery · 2019Review
- Inflammation in sickle cell disease.Clinical hemorheology and microcirculation · 2018Article
- Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.Blood advances · 2017Review
- Increased Vasoocclusive Crises in "O" Blood Group Sickle Cell Disease Patients: Association with Underlying Thrombospondin Levels.Mediterranean journal of hematology and infectious diseases · 2017Article
- Sickle cell disease: an inherited thrombophilia.Hematology. American Society of Hematology. Education Program · 2016Review
- Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.Blood reviews · 2016Review
- Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Blood · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD, we conducted a double-blind, randomized, placebo-controlled study.
methodsThe primary endpoint, safety, was measured by hemorrhagic events requiring medical intervention. Patients were randomized to prasugrel 5 mg daily (n = 41) or placebo (n = 21) for 30 days. Platelet function by VerifyNow® P2Y12 and vasodilator-stimulated phosphoprotein assays at days 10 and 30 were significantly inhibited in prasugrel- compared with placebo-treated SCD patients.
resultsThere were no hemorrhagic events requiring medical intervention in either study arm. Mean pain rate (percentage of days with pain) and intensity in the prasugrel arm were decreased compared with placebo. However, these decreases did not reach statistical significance. Platelet surface P-selectin and plasma soluble P-selectin, biomarkers of in vivo platelet activation, were significantly reduced in SCD patients receiving prasugrel compared with placebo. In sum, prasugrel was well tolerated and not associated with serious hemorrhagic events.
conclusionsDespite the small size and short duration of this study, there was a decrease in platelet activation biomarkers and a trend toward decreased pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.